Kengreal (Cangrelor Tetrasodium) Patent Expiration, LOE Window & CMS Spending
Kengreal (Cangrelor Tetrasodium) by Chiesi Usa: FDA Orange Book LOE 2035-07-10, 0 AB generics, $171K 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Chiesi Usa |
| FDA Application & Pathway | N204958 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2035-07-10 |
| Orange Book Patents (*PED Extensions) | 7 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $171K |
| 2024 Medicare Part D Spend | $0 |
| 2024 Medicaid Spend | $171K |
| Reported Wholesale Price Change (CA SB 17) | 4 WAC filings (max 20.2% 2-yr change) |